NEWOther
Regeneron Reports 73% Response Rate in Ovarian Cancer Drug Trial
Published on Β· Source: investing.com
AI Summary
Summarized by AI from the source belowRegeneron Pharmaceuticals reported a 73% response rate in its ongoing ovarian cancer drug trial. This high response rate demonstrates promising efficacy for the treatment under investigation. The results could lead to further development and eventual market release, which may impact Regeneron's revenue potential significantly. For investors, the success of this trial could be crucial, influencing future stock performance for Regeneron (REGN).
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
